Coherus Oncology Inc’s recently made public that its Director Wahlstrom Mats unloaded Company’s shares for reported $73881.0 on May 23 ’25. In the deal valued at $0.74 per share,99,988 shares were sold. As a result of this transaction, Wahlstrom Mats now holds 0 shares worth roughly $0.0.
UBS downgraded its Coherus Oncology Inc [CHRS] rating to a Neutral from a a Buy in a research note published on August 16, 2024; the price target was decreased to $1.50 from $4. A number of analysts have revised their coverage, including Robert W. Baird’s analysts, who began to cover the stock in mid November with a ‘”an Outperform”‘ rating. Maxim Group also remained covering CHRS and has decreased its forecast on November 08, 2023 with a “Hold” recommendation from previously “Buy” rating. Citigroup started covering the stock on July 24, 2023. It rated CHRS as “a Buy”.
Price Performance Review of CHRS
On Monday, Coherus Oncology Inc [NASDAQ:CHRS] saw its stock jump 2.94% to $0.85. Over the last five days, the stock has gained 11.54%. Coherus Oncology Inc shares have fallen nearly -38.09% since the year began. Nevertheless, the stocks have fallen -52.80% over the past one year. While a 52-week high of $2.43 was reached on 01/06/25, a 52-week low of $0.66 was recorded on 05/15/25. SMA at 50 days reached $0.8907, while 200 days put it at $1.0904.
Levels Of Support And Resistance For CHRS Stock
The 24-hour chart illustrates a support level at 0.8239, which if violated will result in even more drops to 0.7935. On the upside, there is a resistance level at 0.8924. A further resistance level may holdings at 0.9305. The Relative Strength Index (RSI) on the 14-day chart is 51.35, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 0.0361, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bullish at 27.64%. Stochastics %K at 76.75% indicates the stock is a holding.
The most recent change occurred on May 01, 2023 when Truist began covering the stock and recommended ‘”a Buy”‘ rating along with a $24 price target.
